Socrates Health Solutions

Executive Summary

Socrates Health Solutions, founded in 2018 and based in New York, is developing a non-invasive, AI-driven continuous glucose monitoring (CGM) system aimed at eliminating finger pricks and calibration needles for diabetes management. The company's core value proposition is a pain-free, accurate, and affordable solution that leverages machine learning to analyze biometric data, potentially disrupting the traditional CGM market. While still in private stages with no disclosed funding or valuation, the company operates in the rapidly growing digital health sector, where demand for non-invasive monitoring is high. The technology faces significant technical and regulatory hurdles, but if successful, could address the needs of millions of diabetes patients globally. The current lack of public data on clinical progress and financial backing introduces uncertainty, underscoring the early-stage risk.

Upcoming Catalysts (preview)

• Q1 2027Initiation of pivotal clinical trial for non-invasive CGM40% success
• Q2 2027FDA submission for 510(k) clearance or breakthrough designation25% success
• Q3 2026Series A funding round or strategic partnership60% success